In 2021, Lillian L. Siu, MD, and Elaine R. Mardis, PhD, FAACR, each received a call from AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), asking if they’d be interested in serving as...
The FDA has approved the inhibitor entrectinib for some patients 1 month of age or older with solid tumors harboring a certain genetic mutation. The U.S. Food and Drug Administration (FDA) has granted accelerated...
Immunotherapy drug approved as pre- and post-surgery treatment for non-small cell lung cancer, and bladder cancer patients who respond to chemotherapy and immunotherapy can forgo surgery.
Neuroblastoma, a rare cancer that occurs primarily in children, is a scientific paradox, said pediatric oncologist John M. Maris, MD, of Children’s Hospital of Philadelphia (CHOP). “On one hand, a fairly high percentage of...
Researchers share approaches for improving participation among underrepresented groups at AACR conference.
As the number of targeted cancer therapeutics has increased, the percentage of tumors carrying molecular alterations eligible for treatment by those drugs nearly doubled from 2017 to 2022. Precise, biomarker-guided therapies made up almost...
The AACR Annual Meeting 2023, held April 14-19, commemorated several milestones, including the 25th anniversary of the approval of the blockbuster breast cancer drug trastuzumab (Herceptin). Coincidentally, Lisa Coussens, PhD, MD (hc), FAACR, FAIO,...
by Ashok Venkitaraman, MBBS, PhD Singapore will hold its 15th Frontiers in Cancer Science (FCS) conference November 6-8 at the University Cultural Centre, National University of Singapore (NUS). This annual conference started in 2009...
The FDA has approved pembrolizumab for the treatment of certain surgically removable tumors before and after resection. The U.S. Food and Drug Administration (FDA) has approved the immunotherapy pembrolizumab (Keytruda) for use in combination...
The FDA approved nivolumab for some patients with melanoma whose tumor was completely removed through surgery and has not spread. The U.S. Food and Drug Administration (FDA) has approved the checkpoint inhibitor nivolumab (Opdivo)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now